Market revenue in 2023 | USD 307.8 million |
Market revenue in 2030 | USD 1,170.9 million |
Growth rate | 21% (CAGR from 2023 to 2030) |
Largest segment | Symptomatic treatment |
Fastest growing segment | Symptomatic Treatment |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Symptomatic Treatment |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to huntingtons disease treatment market will help companies and investors design strategic landscapes.
Symptomatic treatment was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the U.S. huntingtons disease treatment market based on symptomatic treatment covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. Huntington’s disease treatment market is anticipated to witness significant growth over the forecast period owing to rising prevalence of the disease coupled with product development for HD treatment. According to National Organization for Rare Disorders, around 30,000 patients are affected with HD in the U.S., and the disease generally develops in population aged 30 to 50.
Research grants by nonprofit organizations, such as Huntington’s Disease Society of America, for development of disease treatment are expected to support market growth. The availability of products such as Xenazine and Austedo by H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., respectively, in the region is expected to contribute to market growth.
In April 2017, Teva Pharmaceutical Industries Ltd. received the U.S. FDA approval for launch of Austedo (deutetrabenazine) for treating chorea in patients suffering from HD. Chorea affects around 90% of HD patients, which is characterized by sudden involuntary writhing movements.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. huntingtons disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. huntingtons disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account